The scourge of substandard and falsified medical products gets worse with COVID-19 pandemic

Pan Afr Med J. 2020 Dec 15:37:344. doi: 10.11604/pamj.2020.37.344.26322. eCollection 2020.

Abstract

Although health professionals, communities, governments and global institutions work closely to halt the spread of COVID-19 and mitigate its societal impact, COVID-19 remains a challenge to many countries around the world. In addition to its direct health, economic and social consequences, the pandemic has also resulted in unforeseen consequences in Africa especially in East African countries. COVID-19 might increase the demand and consumption of Substandard and Falsified (SF) medical products in three major ways. The first way is due to the inability of vulnerable segment of the population to access healthcare services as they used to do before. The second way people get exposed to SF medical products is due to fear of being quarantined, isolated and traced. Yet another way is related to import permits for medical products. Concerned regulatory bodies shall intervene aggressively in ensuring the safety, quality and effectiveness of medical products before we face a parallel pandemic from SF medical products.

Keywords: COVID-19; Substandard; falsified; regulatory body.

MeSH terms

  • Africa
  • COVID-19*
  • Delivery of Health Care / organization & administration
  • Delivery of Health Care / standards*
  • Health Services Accessibility*
  • Humans
  • Pharmaceutical Preparations / standards
  • Vulnerable Populations

Substances

  • Pharmaceutical Preparations